left
Hey There : )
right
company-image

Unlisted Shares

Intas Pharmaceuticals Essentials

As of July 24, 2024, Intas Pharmaceuticals, Unlisted Shares are trading at ₹5800.00 per share, with a 52-week high of ₹5800 and 52-week low of ₹5800. The minimun lot size is None shares, and the shares are traded on .

ISIN

INE316F01011

Face Value

₹ 10

Total Share

11,47,67,049

Total Income

₹ 19,882.83 undefined

Profit After Tax

₹ ****

EPS

₹ ****

P/E

****

P/B

****

Market Capitalisation

₹ 66,564.89 Cr

Enterprise Value

₹ ****

Book Value

₹ 1,390.08

Intrinsic Value

₹ ****

Dividend Yield

0.11 %

Earnings Yield

3.64 %

Sector

Health Care

Sub-sector

Pharmaceuticals

Category

Mid Cap

Cashflow - Operations

3,284.12

Cashflow - Financing

-₹ 1,365.09

Intas Pharmaceuticals Growth

Compounded Sales Growth

1 Year

4 Year

6 Year

Compounded Profit Growth

1 Year

4 Year

6 Year

Return On Equity

2018

2021

2023

Highlights

image
  • Global Presence -  Intas Pharmaceuticals has a strong global presence, with operations in over 85 countries worldwide. The company's has a product portfolio of > 10,000 across various international markets such as Asia, Africa, Europe, Latin America, and North America. It is worth noting that the company earns >60% of its revenue from overseas markets such as Europe/Asia, hence the company is always exposed to foreign policy changes. However, the company's hedging strategy mitigates the majority of the risk. 
image
  • Revenue Growth - The company's revenue has experienced a substantial rise, climbing from ₹18,351 crore in FY22 to ₹19,882 crore in FY23, indicating a growth rate of 8.25%. Over the past five years, the company's revenue has consistently increased, achieving a compound annual growth rate (CAGR) of 13.07% from FY18 to FY23.
image
  • Profitability - The company's profitability has maintained consistency over time. The EBIT margin, which was 19.7% in FY18, has decreased to 15.3% in FY23, reflecting a CAGR of -4.95%. Likewise, the net profit margin of the company has also been almost consistent from 12.3% in FY18 to 12.3% in FY23. The net profit has increased by a CAGR OF 12.1% over past 5 years. The profitability has decreased in FY23 compared to FY22 due to the increased costs. It is worth noting that the increase in expenses is related to ESOP liquidation. In FY23, the company has issued the shares for Rs. 5,475 
image
  • Investment Thesis - When benchmarking Intas Pharmaceuticals against industry peers, the average price-to-earnings (P/E) ratio is approximately 32.17x. Factoring in the discounts, the share price falls within the range of ₹4,753 to ₹5,092. Given the positive indicators in terms of revenue growth and profitability, the company appears to be fairly valued, presenting a promising investment opportunity for investors.
  • Kindly note, that the company has received a warning letter from the FDA against its manufacturing facility in Ahmedabad. Any further regulatory non-compliance issued to the company for its products and/or manufacturing facilities, which may impact its product launches and, thus revenues and profitability, would also be a negative trigger. Hence, in the future, the rating may be downgraded if there is any decline in the company’s revenues and profitability and/or an increase in debt levels, leading to an increase in net debt/ OPBDITA to above 1.0x on a sustained basis. Large debt-funded inorganic investments by the company or any adverse outcome of ongoing litigations would remain an event risk, and the impact of the same on the company’s business and credit profile would be monitored on a case-by-case basis.
  • The company consistently maintains a decent dividend yield over the years. However, it's noteworthy that a significant portion of the shareholdings is held by the founders. This suggests that the founders are withdrawing wealth from the business rather than reinvesting it to enhance shareholder value.

Business Rating

image

Managment

lock starlock starlock starlock starlock star
image

Accounting Practice

lock starlock starlock starlock starlock star
image

Profatibility

lock starlock starlock starlock starlock star
image

Solvency

lock starlock starlock starlock starlock star
image

Growth

lock starlock starlock starlock starlock star
image

Valuation

lock starlock starlock starlock starlock star

Overall Ratings

lock starlock starlock starlock starlock star

Recommendation

lock starlock starlock starlock starlock star

Our Team

Quantity

Invest

, Min. Investment: ₹